Latest1 information on COVID-19
©2022 Stanford Medicine
Not Recruiting
Trial ID: NCT02216409
A First-in-Human Phase 1 Dose Escalation Trial of Hu5F9-G4 in Patients With Advanced Solid Malignancies
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Professor of Medicine (Oncology)
The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)
Inclusion Criteria:
Patients with histologically or cytologically confirmed advanced solid malignancy or
Lymphoma
Relapsed or refractory disease after at least 1 prior systemic treatment for the primary
malignancy and not a candidate for other curative treatment.
Adequate hematologic status
Adequate coagulation function
Adequate hepatic function
Adequate renal function
Exclusion Criteria:
Known primary tumors of central nervous system disease
Known active brain metastases
Known cardiopulmonary disease
drug: Hu5F9-G4
Not Recruiting
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
1-650-498-7061